Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Ipsen has been given accelerated approval by the FDA for Iqirvo, which becomes the first dual PPAR alpha/delta agonist for rare cholestatic liver disease primary biliary cholangitis (PBC).

Too much bile in the body can lead to inflammation and damage to the liver. Livdelzi is usually taken together with another medicine for PBC called ursodeoxycholic acid (also called ursodiol or urso).

Apoptotic cell death is regarded as an important pathogenetic mechanism in the major immune-mediated liver diseases, primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis.

I wasn't ill apart from some tiredness.” After being on the organ donor waiting list for four months, Mandy was matched with ...

The different mechanisms by which cholestatic and parenchymal liver disease ... of metabolic bone disease was observed between patients with primary biliary cirrhosis and those with primary ...

Explore how the liver functions, common liver conditions, and tips to maintain liver health through lifestyle changes like ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

And there was.” Mandy, from Newcastle-under-Lyme in Staffordshire, was diagnosed with primary biliary cholangitis (PBC), a liver disease which causes liver failure. The condition also leaves ...